Skip to main content
Log in

Barrier Repair Therapy in Atopic Dermatitis: An Overview

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Atopic eczema or dermatitis (AD) is a chronically relapsing dermatitis associated with pruritus, sleep disturbance, psychosocial symptoms, and impaired quality of life. It affects 10–20 % of school-aged children, and there is evidence to suggest that this prevalence is increasing. Filaggrin (filament-aggregating protein) has an important function in epidermal differentiation and barrier function. Null mutations within the filaggrin gene cause ichthyosis vulgaris and appear to be a major risk factor for developing AD. The affected skin of atopic individuals is deficient in filaggrin degradation products or ceramides. Avoidance of triggering factors, optimal skin care, topical corticosteroids, and calcineurin inhibitors are the mainstays of therapy for AD. Proper moisturizer therapy can reduce the frequency and intensity of flares, as well as the need for topical corticosteroids or topical calcineurin inhibitors. Recent advances in the understanding of the pathophysiological process of AD involving filaggrin and ceramides has led to the concept of barrier therapy and the production of new moisturizers and topical skin products targeted to correct reduced amounts of ceramides and natural moisturizing factors in the skin with natural moisturizing factors, ceramides, and pseudoceramide products. Emollients, both creams and ointments, improve the barrier function of the stratum corneum by providing it with water and lipids. Studies on AD and barrier repair treatment show that adequate lipid replacement therapy reduces the inflammation and restores epidermal function. We reviewed 12 randomized trials and 11 cohort studies and found some evidence that certain products had therapeutic efficacy in improving clinical and/or biophysical parameters of patients with AD. Nevertheless, study methods were often flawed and sample sizes were small. Additional research is warranted to better understand the optimal formulary compositions. Also, long-term studies would be important to evaluate whether lipid barrier replacement therapy reduces bacterial colonization or prevents progression of the atopic march.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hon KL, Wang SS, Leung TF. The atopic march: from skin to the airways. Iran J Allergy Asthma, Immunol. 2012;11:73–7.

    Google Scholar 

  2. Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr. 2007;54:241–73.

    Article  PubMed  Google Scholar 

  3. Leung TF, Ma KC, Hon KL, Lam CW, Wan H, Li CY, Chan IH. Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. Pediatr Allergy Immunol. 2003;14(4):296–301.

    Article  PubMed  Google Scholar 

  4. Leung AKC, Barber KA. Managing childhood atopic dermatitis. Adv Therapy. 2003;20(3):129–37.

    Article  Google Scholar 

  5. Leung DY, Jain N, Leo HL. New concepts in the pathogenesis of atopic dermatitis. Curr Opin Immunol. 2003;15(6):634–8.

    Article  PubMed  CAS  Google Scholar 

  6. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151–60.

    Article  PubMed  Google Scholar 

  7. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S86–93.

    Article  PubMed  Google Scholar 

  8. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;2:44–7.

    Google Scholar 

  9. Hanifin JM. Atopic dermatitis. J Am Acad Dermatol. 1982;6(1):1–13.

    Article  PubMed  CAS  Google Scholar 

  10. Leung DY, Nicklas RA, Li JT, Bernstein IL, Blessing-Moore J, Boguniewicz M, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol. 2004;93(3 Suppl 2):S1–21.

    Article  PubMed  Google Scholar 

  11. Marenholz I, Nickel R, Ruschendorf F, Schulz F, Esparza-Gordillo J, Kerscher T, et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol. 2006;118(4):866–71.

    Article  PubMed  CAS  Google Scholar 

  12. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.[see comment]. Nat Genet. 2006;38(4):441–6.

    Article  PubMed  CAS  Google Scholar 

  13. Sandilands A, Terron-Kwiatkowski A, Hull PR, O’Regan GM, Clayton TH, Watson RM, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet. 2007;39(5):650–4.

    Article  PubMed  CAS  Google Scholar 

  14. Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin’s fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol. 2007;127:1282–4.

    Article  PubMed  CAS  Google Scholar 

  15. Ching G, Hon KL. Filaggrin null mutations in childhood atopic dermatitis among the Chinese. Int J Immunogenet. 2009;36(4):251–4.

    Article  PubMed  CAS  Google Scholar 

  16. Enomoto H, Hirata K, Otsuka K, Kawai T, Takahashi T, Hirota T, et al. Filaggrin null mutations are associated with atopic dermatitis and elevated levels of IgE in the Japanese population: a family and case-control study. J Hum Genet. 2008;53(7):615–21.

    Article  PubMed  CAS  Google Scholar 

  17. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol. 2005;6(4):328–40.

    Article  PubMed  CAS  Google Scholar 

  18. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122(4):812–24.

    Article  PubMed  Google Scholar 

  19. Thulin CD, Taylor JA, Walsh KA. Microheterogeneity of human filaggrin: analysis of a complex peptide mixture using mass spectrometry. Protein Sci. 1996;5(6):1157–64.

    Article  PubMed  CAS  Google Scholar 

  20. Bikle DD, Chang S, Crumrine D, Elalieh H, Man MQ, Choi EH, et al. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. J Invest Dermatol. 2004;122(4):984–92.

    Article  PubMed  CAS  Google Scholar 

  21. O’Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40(7):965–72.

    Article  PubMed  Google Scholar 

  22. Rousseau M, Bedouet L, Lati E, Gasser P, Le NK, Lopez E. Restoration of stratum corneum with nacre lipids. Comp Biochem Physiol B Biochem Mol Biol. 2006;145(1):1–9.

    Article  PubMed  Google Scholar 

  23. Jungersted JM, Scheer H, Mempel M, Baurecht H, Cifuentes L, Hogh JK, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010;65(7):911–8.

    Article  PubMed  CAS  Google Scholar 

  24. Hara J, Higuchi K, Okamoto R, Kawashima M, Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol. 2000;115(3):406–13.

    Article  PubMed  CAS  Google Scholar 

  25. Ishikawa J, Narita H, Kondo N, Hotta M, Takagi Y, Masukawa Y, et al. Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatol. 2010;130(10):2511–4.

    Article  PubMed  CAS  Google Scholar 

  26. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651–7.

    PubMed  CAS  Google Scholar 

  27. Park KY, Kim DH, Jeong MS, Li K, Seo SJ. Changes of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide-dominant emollient in patients with atopic dermatitis. J Korean Med Sci. 2010;25(5):766–71.

    Article  PubMed  CAS  Google Scholar 

  28. Hon KL, Wong KY, Leung TF, Chow CM, Ng PC. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD Index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol. 2008;9(1):45–50.

    Article  PubMed  Google Scholar 

  29. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis [see comment]. N Engl J Med. 2002;347(15):1151–60.

    Article  PubMed  CAS  Google Scholar 

  30. Heimall J, Spergel JM. Filaggrin mutations and atopy: consequences for future therapeutics. Expert Rev Clin Immunol. 2012;8(2):189–97.

    Article  PubMed  CAS  Google Scholar 

  31. Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol. 2011;4(9):22–42.

    PubMed  Google Scholar 

  32. Masukawa Y, Narita H, Sato H, Naoe A, Kondo N, Sugai Y, et al. Comprehensive quantification of ceramide species in human stratum corneum. J Lipid Res. 2009;50(8):1708–19.

    Article  PubMed  CAS  Google Scholar 

  33. van Smeden J, Hoppel L, van der Heijden R, Hankemeier T, Vreeken RJ, Bouwstra JA. LC/MS analysis of stratum corneum lipids: ceramide profiling and discovery. J Lipid Res. 2011;52(6):1211–21.

    Article  PubMed  Google Scholar 

  34. Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res. 2012;53:2755–66.

    Article  PubMed  CAS  Google Scholar 

  35. Sugarman JL. The epidermal barrier in atopic dermatitis. Semin Cutan Med Surg. 2008;27(2):108–14.

    Article  PubMed  CAS  Google Scholar 

  36. Anderson PC, Dinulos JG. Are the new moisturizers more effective? Curr Opin Pediatr. 2009;21(4):486–90.

    Article  PubMed  Google Scholar 

  37. Sajic D, Asiniwasis R, Skotnicki-Grant S. A look at epidermal barrier function in atopic dermatitis: physiologic lipid replacement and the role of ceramides. Skin Therapy Lett. 2012;17(7):6–9.

    PubMed  CAS  Google Scholar 

  38. Bleton J, Gaudin K, Chaminade P, Goursaud S, Baillet A, Tchapla A. Structural analysis of commercial ceramides by gas chromatography-mass spectrometry. J Chromatogr A. 2001;917(1–2):251–60.

    PubMed  CAS  Google Scholar 

  39. Kang JS, Yoon WK, Youm JK, Jeong SK, Park BD, Han MH, et al. Inhibition of atopic dermatitis-like skin lesions by topical application of a novel ceramide derivative, K6PC-9p, NC/Nga mice. Exp Dermatol. 2008;17(11):958–64.

    Article  PubMed  CAS  Google Scholar 

  40. Hon KL, Leung AK. Use of ceramides and related products for childhood-onset eczema. Recent Pat Inflamm Allergy Drug Discov. 2013;7(1):12–9.

    Article  PubMed  CAS  Google Scholar 

  41. Hon KL, Ching GK, Leung TF, Choi CY, Lee KK, Ng PC. Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2010;35(1):22–6.

    Article  PubMed  CAS  Google Scholar 

  42. Hon KL, Leung T, Wong Y, Li A, Fok T, et al. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol. 2005;30(4):351–4.

    Article  PubMed  CAS  Google Scholar 

  43. Sehra S, Tuana FM, Holbreich M, Mousdicas N, Tepper RS, Chang CH, et al. Scratching the surface: towards understanding the pathogenesis of atopic dermatitis. Crit Rev Immunol. 2008;28(1):15–43.

    Article  PubMed  CAS  Google Scholar 

  44. Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47(2):198–208.

    Article  PubMed  Google Scholar 

  45. Maintz L, Novak N. Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol. 2007;17(4):267–83.

    PubMed  CAS  Google Scholar 

  46. Cork MJ, Danby S. Skin barrier breakdown: a renaissance in emollient therapy. Br J Nursing. 2009;18(14):872–7.

    Google Scholar 

  47. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892–908.

    Article  PubMed  CAS  Google Scholar 

  48. Tarr A, Iheanacho I. Should we use bath emollients for atopic eczema? BMJ. 2009;339:b4273.

    Article  PubMed  Google Scholar 

  49. Roos TC, Geuer S, Roos S, Brost H. Recent advances in treatment strategies for atopic dermatitis. Drugs. 2004;64(23):2639–66.

    Article  PubMed  CAS  Google Scholar 

  50. Baumer JH. Atopic eczema in children, NICE. Arch Dis Child Educ Pract Ed. 2008;93(3):93–7.

    PubMed  CAS  Google Scholar 

  51. Hon KL, Wang SS, Pong NH, Leung TF. The ideal moisturizer: a survey of parental expectations and practice in childhood-onset eczema. J Dermatol Treat. 2013;24:7–12.

    Article  Google Scholar 

  52. Dohil MA, Eichenfield LF. A treatment approach for atopic dermatitis. Pediatr Ann. 2005;34(3):201–10.

    PubMed  Google Scholar 

  53. Bissonnette R, Maari C, Provost N, Bolduc C, Nigen S, Rougier A, et al. A double-blind study of tolerance and efficacy of a new urea-containing moisturizer in patients with atopic dermatitis. J Cosmet Dermatol. 2010;9(1):16–21.

    Article  PubMed  Google Scholar 

  54. Miller DW, Koch SB, Yentzer BA, Clark AR, O’Neill JR, Fountain J, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011;10(5):531–7.

    PubMed  Google Scholar 

  55. Chamlin SL, Frieden IJ, Fowler A, Williams M, Kao J, Sheu M, et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol. 2001;137(8):1110–2.

    PubMed  CAS  Google Scholar 

  56. Simpson E, Bohling A, Bielfeldt S, Bosc C, Kerrouche N. Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. J Dermatol Treat. 2013;24:122–5.

    Article  CAS  Google Scholar 

  57. Simpson E, Trookman NS, Rizer RL, Preston N, Colon LE, Johnson LA, et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol. 2012;29(5):590–7.

    Article  PubMed  Google Scholar 

  58. Frankel A, Sohn A, Patel RV, Lebwohl M. Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic Acid emollient foam in the treatment of patients with atopic dermatitis. J Drugs Dermatol. 2011;10(6):666–72.

    PubMed  CAS  Google Scholar 

  59. Loden M, Wiren K, Smerud K, Meland N, Honnas H, Mork G, et al. Treatment with a barrier-strengthening moisturizer prevents relapse of hand-eczema: an open, randomized, prospective, parallel group study. Acta Derm Venereol. 2010;90(6):602–6.

    Article  PubMed  Google Scholar 

  60. Grimalt R, Mengeaud V, Cambazard F, Study Investigators’ Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214(1):61–7.

    Article  PubMed  CAS  Google Scholar 

  61. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633–40.

    Article  PubMed  CAS  Google Scholar 

  62. Hon KL, Wang SS, Lau Z, Lee HC, Lee KK, Leung TF, et al. Pseudoceramide for childhood eczema: does it work? Hong Kong Med J. 2011;17(2):132–6.

    PubMed  CAS  Google Scholar 

  63. Lee YB, Park HJ, Kwon MJ, Jeong SK, Cho SH. Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur J Dermatol. 2011;21(5):710–6.

    PubMed  CAS  Google Scholar 

  64. Park BD, Youm JK, Jeong SK, Choi EH, Ahn SK, Lee SH. The characterization of molecular organization of multilamellar emulsions containing pseudoceramide and type III synthetic ceramide. J Invest Dermatol. 2003;121(4):794–801.

    Article  PubMed  CAS  Google Scholar 

  65. Kim HJ, Park HJ, Yun JN, Jeong SK, Ahn SK, Lee SH. Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids. Allergy Asthma Immunol Res. 2011;3(2):96–102.

    Article  PubMed  CAS  Google Scholar 

  66. Draelos ZD. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis. J Cosmet Dermatol. 2011;10(3):185–8.

    Article  PubMed  Google Scholar 

  67. Nolan K, Marmur E. Moisturizers: reality and the skin benefits. Dermatol Ther. 2012;25(3):229–33.

    Article  PubMed  Google Scholar 

  68. Jungersted JM, Hogh JK, Hellegren LI, Jemec GB, Agner T. Effects of topical corticosteroid and tacrolimus on ceramides and irritancy to sodium lauryl sulphate in healthy skin. Acta Derm Venereol. 2011;91(3):290–4.

    Article  PubMed  Google Scholar 

  69. Draelos ZD. The effect of ceramide-containing skin care products on eczema resolution duration. Cutis. 2008;81(1):87–91.

    PubMed  Google Scholar 

  70. Madaan A. Epiceram for the treatment of atopic dermatitis. Drugs Today. 2008;44(10):751–5.

    Article  PubMed  CAS  Google Scholar 

  71. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009;8(12):1106–11.

    PubMed  Google Scholar 

  72. Lowe AJ, Tang ML, Dharmage SC, Varigos G, Forster D, Gurrin LC, et al. A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates. BMC Dermatol. 2012;4(12):3.

    Article  Google Scholar 

  73. Cox H, Lloyd K, Williams H, Arkwright PD, Brown T, Clark C, et al. Emollients, education and quality of life: the RCPCH care pathway for children with eczema. Arch Dis Child. 2011;96(Suppl 2):i19–24.

    Article  PubMed  Google Scholar 

  74. Loden M, Andersson AC, Andersson C, Frodin T, Oman H, Lindberg M. Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis. Skin Res Technol. 2001;7(4):209–13.

    Article  PubMed  CAS  Google Scholar 

  75. Xhauflaire-Uhoda E, Thirion L, Pierard-Franchimont C, Pierard GE. Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis. Dermatology. 2007;214(4):328–32.

    Article  PubMed  CAS  Google Scholar 

  76. Breternitz M, Kowatzki D, Langenauer M, Elsner P, Fluhr JW. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21(1):39–45.

    Article  PubMed  CAS  Google Scholar 

  77. Aschoff R, Schwanebeck U, Brautigam M, Meurer M. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis. Exp Dermatol. 2009;18(1):24–9.

    Article  PubMed  CAS  Google Scholar 

  78. Jensen JM, Pfeiffer S, Witt M, Brautigam M, Neumann C, Weichenthal M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol. 2009;123(5):1124–33.

    Article  PubMed  CAS  Google Scholar 

  79. Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol. 2009;23(11):1267–72.

    Article  PubMed  CAS  Google Scholar 

  80. Berardesca E, Abril E, Serio M, Cameli N. Effects of topical gluco-oligosaccharide and collagen tripeptide F in the treatment of sensitive atopic skin. Int J Cosmet Sci. 2009;31(4):271–7.

    Article  PubMed  CAS  Google Scholar 

  81. Woods MT, Brown PA, Baig-Lewis SF, Simpson EL. Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. J Drugs Dermatol. 2011;10(2):171–6.

    PubMed  Google Scholar 

  82. Kircik LH. Transepidermal water loss (TEWL) and corneometry with hydrogel vehicle in the treatment of atopic dermatitis: a randomized, investigator-blind pilot study. J Drugs Dermatol. 2012;11(2):180–4.

    PubMed  CAS  Google Scholar 

  83. Gehring W, Bopp R, Rippke F, Gloor M. Effect of topically applied evening primrose oil on epidermal barrier function in atopic dermatitis as a function of vehicle. Arzneimittelforschung. 1999;49(7):635–42.

    PubMed  CAS  Google Scholar 

  84. Hjalte F, Asseburg C, Tennvall GR. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden—with model applications for Denmark, Norway and Finland. J Eur Acad Dermatol Venereol. 2010;24(4):474–80.

    Article  PubMed  CAS  Google Scholar 

  85. Hon KL, Pong NH, Wang SS, Lee VW, Luk NM, Leung TF. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D. 2013;13:37–42.

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

No sources of funding were used to prepare this review.

Conflicts of Interest

The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kam Lun Hon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hon, K.L., Leung, A.K.C. & Barankin, B. Barrier Repair Therapy in Atopic Dermatitis: An Overview. Am J Clin Dermatol 14, 389–399 (2013). https://doi.org/10.1007/s40257-013-0033-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-013-0033-9

Keywords

Navigation